Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Flecainide: Current status and perspectives in arrhythmia management.

Literature DB >> 25717355

Flecainide: Current status and perspectives in arrhythmia management.

George K Andrikopoulos¹, Sokratis Pastromas¹, Stylianos Tzeis¹.

Abstract

Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as maintenance of sinus rhythm in patients with atrial fibrillation and/or supraventricular tachycardias. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is not recommended in patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations. We herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronary artery disease.

Entities: Chemical Disease Species

Keywords: Atrial fibrillation; Class IC antiarrhythmic drugs; Flecainide; Proarrhythmia; Ventricular tachycardia

Year: 2015 PMID： 25717355 PMCID： PMC4325304 DOI： 10.4330/wjc.v7.i2.76

Source DB: PubMed Journal: World J Cardiol

63 in total

1. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.

Authors: Paolo Alboni; Giovanni L Botto; Giuseppe Boriani; Giovanni Russo; Federico Pacchioni; Matteo Iori; Giovanni Pasanisi; Marina Mancini; Barbara Mariconti; Alessandro Capucci
Journal: Heart Date: 2010-04 Impact factor: 5.994

2. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors: Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal: J Am Coll Cardiol Date: 2011-05-31 Impact factor: 24.094

3. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide.

Authors: T J Campbell; E M Vaughan Williams
Journal: Cardiovasc Res Date: 1983-05 Impact factor: 10.787

4. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.

Authors: Nian Liu; Marco Denegri; Yanfei Ruan; José Everardo Avelino-Cruz; Andrea Perissi; Sara Negri; Carlo Napolitano; William A Coetzee; Penelope A Boyden; Silvia G Priori
Journal: Circ Res Date: 2011-06-16 Impact factor: 17.367

5. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.

Authors: I C Van Gelder; H J Crijns; W H Van Gilst; L M Van Wijk; H P Hamer; K I Lie
Journal: Am J Cardiol Date: 1989-12-01 Impact factor: 2.778

6. [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].

Authors: A Carunchio; M S Fera; A Mazza; M Burattini; G Greco; A Galati; V Ceci
Journal: G Ital Cardiol Date: 1995-01

7. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.

Authors: G Boriani; M Biffi; A Capucci; G Botto; T Broffoni; M Ongari; G Trisolino; I Rubino; M Sanguinetti; A Branzi; B Magnani
Journal: Pacing Clin Electrophysiol Date: 1998-11 Impact factor: 1.976

8. Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias.

Authors: K J Hellestrand; A W Nathan; R S Bexton; R A Spurrell; A J Camm
Journal: Am J Cardiol Date: 1983-03-01 Impact factor: 2.778

9. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.

Authors: Hiroshi Watanabe; Christian van der Werf; Ferran Roses-Noguer; Arnon Adler; Naokata Sumitomo; Christian Veltmann; Raphael Rosso; Zahurul A Bhuiyan; Hennie Bikker; Prince J Kannankeril; Minoru Horie; Tohru Minamino; Sami Viskin; Björn C Knollmann; Jan Till; Arthur A M Wilde
Journal: Heart Rhythm Date: 2012-12-31 Impact factor: 6.343

10. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

Authors: A H Pietersen; H Hellemann
Journal: Am J Cardiol Date: 1991-04-01 Impact factor: 2.778

15 in total

1. Modeling the human Na_v1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade.

Authors: Marawan Ahmed; Horia Jalily Hasani; Aravindhan Ganesan; Michael Houghton; Khaled Barakat
Journal: Drug Des Devel Ther Date: 2017-08-04 Impact factor: 4.162

Review 2. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia.

Authors: Isabelle Malhamé; Christy Gandhi; Gofran Tarabulsi; Matthew Esposito; Kristin Lombardi; Antony Chu; Kenneth K Chen
Journal: Obstet Med Date: 2018-11-15

3. A broad complex tachycardia in a patient on flecainide.

Authors: Debjit Chatterjee
Journal: Br J Cardiol Date: 2021-07-14

Review 4. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors: Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal: Heart Fail Rev Date: 2019-03 Impact factor: 4.214

5. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.

Authors: Robert C Klipp; Na Li; Qiongling Wang; Tarah A Word; Martha Sibrian-Vazquez; Robert M Strongin; Xander H T Wehrens; Jonathan J Abramson
Journal: Heart Rhythm Date: 2017-12-14 Impact factor: 6.343

6. Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure.

Authors: Patrick Connell; Tarah A Word; Xander H T Wehrens
Journal: Expert Opin Ther Targets Date: 2020-01-03 Impact factor: 6.902

Flecainide: Current status and perspectives in arrhythmia management.

1. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.

2. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

3. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide.

4. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.

5. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.

6. [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].

7. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.

8. Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias.

9. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.

10. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

1. Modeling the human Na_v1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade.

Review 2. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia.

3. A broad complex tachycardia in a patient on flecainide.

Review 4. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

5. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.

6. Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure.

7. Flecainide toxicity associated with the use of goji berries: a case report.

8. An electrocardiographic series of flecainide toxicity.

Review 9. Targeting Ca^{2 +} Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Review 10. Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.

Review 2. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia.

Review 4. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Review 9. Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Review 10. Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.

Review 9. Targeting Ca^{2 +} Handling Proteins for the Treatment of Heart Failure and Arrhythmias.